105 related articles for article (PubMed ID: 9684930)
21. Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (Tomudex) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia.
Ek O; Reaman GH; Crankshaw DL; Chelstrom LM; Myers DE; Uckun FM
Leuk Lymphoma; 1998 Feb; 28(5-6):509-14. PubMed ID: 9613980
[TBL] [Abstract][Full Text] [Related]
22. Targeting colon cancer cells with genistein-17.1A immunoconjugate.
Gentile MS; Vasu C; Green A; Murillo G; Das Gupta TK; Constantinou AI; Prabhakar BS; Salti GI
Int J Oncol; 2003 May; 22(5):955-9. PubMed ID: 12684659
[TBL] [Abstract][Full Text] [Related]
23. Toxicity profile of the investigational new biotherapeutic agent, B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
Gunther R; Chelstrom LM; Wendorf HR; Schneider EA; Covalciuc K; Johnson B; Clementson D; Irvin JD; Myers DE; Uckun FM
Leuk Lymphoma; 1996 Jun; 22(1-2):61-70, follow.186, color plate II-V. PubMed ID: 8724529
[TBL] [Abstract][Full Text] [Related]
24. Engagement of the CD19 receptor on human B-lineage leukemia cells activates LCK tyrosine kinase and facilitates radiation-induced apoptosis.
Waddick KG; Chae HP; Tuel-Ahlgren L; Jarvis LJ; Dibirdik I; Myers DE; Uckun FM
Radiat Res; 1993 Dec; 136(3):313-9. PubMed ID: 7506428
[TBL] [Abstract][Full Text] [Related]
25. Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase.
Ek O; Gaynon P; Zeren T; Chelstrom LM; Myers DE; Uckun FM
Leuk Lymphoma; 1998 Sep; 31(1-2):143-9. PubMed ID: 9720724
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond.
Katz BZ; Herishanu Y
Leuk Lymphoma; 2014 May; 55(5):999-1006. PubMed ID: 23885836
[TBL] [Abstract][Full Text] [Related]
27. Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment.
Li Z; Wang M; Yao X; Li H; Li S; Liu L; Yu D; Li X; Fang J; Huang C
Int Immunopharmacol; 2018 Sep; 62():299-308. PubMed ID: 30048860
[TBL] [Abstract][Full Text] [Related]
28. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo.
Noujaim AA; Schultes BC; Baum RP; Madiyalakan R
Cancer Biother Radiopharm; 2001 Jun; 16(3):187-203. PubMed ID: 11471484
[TBL] [Abstract][Full Text] [Related]
29. Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule.
Myers DE; Yanishevski Y; Masson E; Irvin JD; Evans WE; Uckun FM
Leuk Lymphoma; 1995 Jun; 18(1-2):93-102. PubMed ID: 8580835
[TBL] [Abstract][Full Text] [Related]
30. Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13.
Drugs R D; 2006; 7(6):379-83. PubMed ID: 17073521
[TBL] [Abstract][Full Text] [Related]
31. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.
Liu XY; Pop LM; Tsai L; Pop IV; Vitetta ES
Int J Cancer; 2011 Jul; 129(2):497-506. PubMed ID: 20878959
[TBL] [Abstract][Full Text] [Related]
32. In vivo toxicity, pharmacokinetic features, and immunogenicity of B43(Anti-CD19)-genistein immunoconjugate in mice and non-human primates.
Myers DE; Uckun FM
J Med Food; 1999; 2(3-4):173-5. PubMed ID: 19281372
[No Abstract] [Full Text] [Related]
33. Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside.
Messinger Y; Yanishevski Y; Avramis VI; Ek O; Chelstrom LM; Gunther R; Myers DE; Irvin JD; Evans W; Uckun FM
Clin Cancer Res; 1996 Sep; 2(9):1533-42. PubMed ID: 9816330
[TBL] [Abstract][Full Text] [Related]
34. Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen.
Stan AC; Radu DL; Casares S; Bona CA; Brumeanu TD
Cancer Res; 1999 Jan; 59(1):115-21. PubMed ID: 9892195
[TBL] [Abstract][Full Text] [Related]
35. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy.
Scheuermann RH; Racila E
Leuk Lymphoma; 1995 Aug; 18(5-6):385-97. PubMed ID: 8528044
[TBL] [Abstract][Full Text] [Related]
36. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
[TBL] [Abstract][Full Text] [Related]
37. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
[TBL] [Abstract][Full Text] [Related]
38. Preparation and identification of a novel immunomodulator composed of muramyl dipeptide and anti-CD10 monoclonal antibody for treatment of minimal residual disease in acute leukemia children.
Wang LZ; Sun LR; Zhao YX; Wang LL
Int Immunopharmacol; 2011 Sep; 11(9):1211-9. PubMed ID: 21492747
[TBL] [Abstract][Full Text] [Related]
39. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
Multani PS; O'Day S; Nadler LM; Grossbard ML
Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
[TBL] [Abstract][Full Text] [Related]
40. Crystal structure of B-cell co-receptor CD19 in complex with antibody B43 reveals an unexpected fold.
Teplyakov A; Obmolova G; Luo J; Gilliland GL
Proteins; 2018 May; 86(5):495-500. PubMed ID: 29490423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]